Pediatrics Doctors in Brecksville, OH Accepting Medicare

6 Pediatrics doctors found. Showing 1 - 6

Carrie Ann Bohenick, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 7001 S Edgerton Rd Ste 500, Brecksville, OH 44141 Phone: 440-526-4543    Fax: 440-526-6126

Lynn Maruskin, CNP Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6909 Royalton Rd Ste 304, Brecksville, OH 44141 Phone: 216-383-0100    Fax: 216-383-6481

John Trudeau, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6418 Oakes Rd, Brecksville, OH 44141 Phone: 440-665-3898

Michelle Levy, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6909 Royalton Rd Ste 304, Brecksville, OH 44141 Phone: 440-526-8222    Fax: 440-526-7881

Elizabeth Hagen, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 6909 Royalton Rd Ste 304, Brecksville, OH 44141 Phone: 216-383-0100    Fax: 216-383-6481

Mark Raymond Evans, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 7001 S Edgerton Rd Ste 500, Brecksville, OH 44141 Phone: 440-526-4543    Fax: 440-526-6126

News Archive

Warning signs of an ischemic stroke may be evident as early as seven days before an attack

Warning signs of an ischemic stroke may be evident as early as seven days before an attack and require urgent treatment to prevent serious damage to the brain, according to a study of stroke patients published in the March 8, 2005 issue of Neurology, the scientific journal of the American Academy of Neurology.

Doctors' religious beliefs affect how they provide end-of-life care, Study finds

A doctor's own religious practice can become quite relevant to patient care, especially when end of life issues come into play. A new study finds that doctors who are not religious are more likely to take steps to help end a very sick patient's life, and to discuss these kinds of decisions, than doctors who are very religious.

Dynavax commences Phase 3 trial for HEPLISAV hepatitis B vaccine

Dynavax Technologies Corporation (Nasdaq:DVAX) today announced the initiation of a Phase 3 registration trial for HEPLISAVTM hepatitis B vaccine in individuals with chronic kidney disease. A second registration trial, a Phase 3 lot-to-lot consistency trial, is expected to begin in early 2010. HEPLISAV is an investigational adult hepatitis B vaccine designed to provide increased, rapid protection with fewer doses than current licensed vaccines.

Gene that causes rare breast cancer identified

Researchers have found that a rare but hard-to-treat form of breast cancer is driven by a newly discovered gene. The gene ZNF703 is the first oncogene to be discovered in five years, and it could lead to more effective treatments down the road, Cancer Research UK said.

Sharing large-scale health data to drive forward precision medicine

Precision medicine requires big data. In order to improve the treatment of individuals with cancer, or to understand rare diseases, scientists and clinicians, as well as AI technologies require access to larger sets of health research data that covers diverse populations and wide ranges of conditions.

Read more Medical News

› Verified 7 days ago